Boehringer Ingelheim is honored as a Med Honors Top Pharmaceutical Innovator for its unwavering commitment to advancing healthcare through innovative research and development. Founded in 1885, this family-owned company has grown into one of the world's leading pharmaceutical enterprises, with a presence in over 130 markets and a workforce of approximately 53,000 employees.

The company's dedication to innovation is evident in its robust pipeline, encompassing around 80 clinical and pre-clinical projects, with the potential to deliver up to 20 new medicine approvals in the next six years.

Boehringer Ingelheim's research focuses on areas with high unmet medical needs, including oncology, respiratory diseases, cardiometabolic conditions, and diseases of the central nervous system.

In oncology, Boehringer Ingelheim has recently entered a collaboration with Circle Pharma to develop first-in-class molecules targeting cancer, demonstrating its commitment to pioneering cancer treatments.

Additionally, the company has received Breakthrough Therapy designation from the U.S. Food and Drug Administration for survodutide, an experimental drug aimed at treating non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), a type of fatty liver disease.

Boehringer Ingelheim's commitment to improving patient access to essential medications is exemplified by its partnership with GoodRx to offer a biosimilar to Humira at a 92% discount, making treatment more affordable for patients.

Through its relentless pursuit of medical breakthroughs and dedication to patient-centric solutions, Boehringer Ingelheim exemplifies the qualities celebrated by the Med Honors awards, solidifying its position as a leader in pharmaceutical innovation.